Healthcare Economist April 30, 2024
Jason Shafrin

In July 2018, FDA released the Biosimilars Action Plan (BAP), which outlined FDA’s approach for expanding access to biosimilars for the American public. The plan focused on 4 key areas:

A recent FDA report reviews some of their accomplishments since then. Most of these efforts revolve around guidance documents, additional staff, education products and websites, public hearings and regulations (i.e., proposed/final rules)....

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech, Survey / Study, Trends
Medical device instructions need a rewrite, APIC says
FDA approves Amgen's treatment for most deadly form of lung cancer
Karius snares FDA breakthrough tag for genomic infectious disease blood test
FDA report highlights need to improve diversity in clinical trials
US Pharma and Biotech Summit 2024: Artificial Intelligence and Machine Learning Through the Eyes of the FDA

Share This Article